Preliminary clinical study on treatment of prostate cancer with Cyber-Knife
10.3760/cma.j.issn.0254-5098.2019.06.003
- VernacularTitle:射波刀治疗前列腺癌初步临床观察
- Author:
Hanjing GAO
1
;
Zhen TAO
;
Huanhuan WANG
;
Fengtong LI
;
Yang DONG
;
Xuyao YU
;
Jingsheng WANG
;
Huaming CHEN
;
Yongchun SONG
;
Zhiyong YUAN
Author Information
1. 天津市第四中心医院放疗科 300140
- Keywords:
Ultra-hypofractionated;
Stereotactic body radiotherapy;
Cyber-Knife;
Prostate cancer;
Prostate-specific antigen
- From:
Chinese Journal of Radiological Medicine and Protection
2019;39(6):415-421
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and effectiveness of ultra-hypofractionated stereotactic body radiotherapy in the treatment of prostate cancer.Methods A total of 26 patients with prostate cancer treated with Cyber-Knife from May 2010 to May 2018 were analyzed retrospectively.The median age of the patients was 69 years old (range,57 to 87).Ultra-hypofractionated radiotherapy was delivered in five fractions of 7.0-7.5 Gy for a total dose of 35.0-37.5 Gy.Androgen deprivation therapy (ADT) was administered in combination with the Cyber-Knife.The primary endpoints were radiation toxicity,PSA-response,local control and symptom alleviation,while the secondary endpoints were progression-free survival and overall survival.Results No graded ≥ 3 acute and late radiation toxicities occurred during follow-up.The acute toxicity of Grades 1 and 2 was 38.4％ and 19.2％,while the late toxicity of Grades 1 and 2 was 30.8％ and 3.8％,respectively.At a median follow-up of 22.44 months,for patients with localized stage,PSA level was decreased significantly after radiotherapy (Z =2.900,2.794,2.510,2.090,P＜0.05).However,there was no statistically significant difference for the metastatic group (P＞ 0.05).Conclusions Ultra-hypofractionated stereotactic body radiotherapy is a safe and effective treatment for patients with prostate cancer.
